Biocon Biologics provided 7,000 doses of Itolizumab in April

The company does not look at Covid-19 related drugs as a business opportunity; it expects higher growth this fiscal year on the back of new biosimilar launches in both emerging and developed markets, Arun Chandavarkar, managing director of Biocon Biologics, told ET in an interview.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news